Investor Relations

Corporate Governance

Russell Angus has served as our Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with over 30 years of experience in commercial execution, operations, and strategic acquisitions. He currently serves on the Board of Directors at InterMune, Inc. and Questcor Pharmaceuticals, Inc. and from 1999 to April, 2013, Mr. Russell served as a Director at Shire Plc. During his tenure at Shire Plc, Mr. Russell served as CEO from 2008 to 2013 and CFO from 1999 to 2008. While CEO at Shire, Mr. Russell was also the Chair of Shire's Leadership Team and a lead member of the Shire Management Committee, which designed and implemented Shire's immensely successful long-term business strategy. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca, most recently as VP of Corporate Finance at AstraZeneca.

Mr. Byrnes has spent over thirty years in the medical device and biotech industry. Most recently from November 2002 to January 2005, he served as the President and Chief Executive Officer of Thermage, Inc. (“Thermage”), a medical device company focused on the non-invasive treatment of wrinkles. From October 1997 until October 2002 and from January 2005 to the present, Mr. Byrnes has served as the President and Chief Executive Officer of Roan, an advisory service for healthcare organizations. Mr. Byrnes has also served as Chairman and Chief Executive Officer of Tokos Medical, President of Caremark and Vice President of Marketing and Business Development for Genentech.

Mr. Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, he has helped build three private healthcare companies -- Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer in 2006.

Dr. Gardner has spent over 25 years in academia, medicine and industry. She began her academic medical career at Stanford University, where she has held several positions including Senior Associate Dean for Education and Student Affairs and remains today as Professor of Medicine. She took a leave of absence to work at ALZA Corporation, a major drug delivery company, as a Principal Scientist, Vice President of Research and as Head of ALZA Technology Institute. She has conducted extensive research in cell biology, including gene therapy, and is widely published in the fields of cell biology and pharmacology. She has received numerous national awards and honors and serves on the Board of Directors of several public and private companies. Dr. Gardner was responsible for Essex Woodlands’ introduction to Rinat Neurosciences, which was acquired by Pfizer, Inc. in April 2006.

Member of the Science & Technology Committee

Mr. Gangolli is President, North America of GW Pharmaceuticals, spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for diverse indications. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400 person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5‐year period. Prior to Allergan, Mr. Gangolli served as Vice President, Sales and Marketing at VIVUS, Inc., where he facilitated the successful transition of the company from a research and development start-up into a niche pharmaceutical company. Before VIVUS, Mr. Gangolli served in a number of increasingly senior marketing roles at Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England

Philip J. Vickers, Ph.D. has served as a director since February 2015. Dr. Vickers has spent over 25 years in the pharmaceutical industry. Since 2011, he has been serving as Global Head of Research and Development at Shire where he is responsible for overseeing preclinical research and development, clinical research, regulatory affairs, and medical affairs. Dr. Vickers is also a member of Shire’s Executive and Pipeline Committees. Prior to Shire, he was Chief Scientific Officer and President at Resolvyx Pharmaceuticals, a biopharmaceutical company, from 2009 to 2011, where he was a member of the board of directors. Prior to Resolvyx, he served in various capacities with international biopharmaceutical companies including Boehringer-Ingelheim Pharmaceuticals Inc., Pfizer and Merck Frosst Centre. Dr. Vickers was a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland and holds a Ph.D. in Biochemistry from the University of Toronto, and a B.S. in Applied Biochemistry from the University of Salford, Manchester.

Chair of the Science & Technology Committee
  Audit Nominating Compensation Science & Technology
Angus C. Russell
Angus C. Russell
Chairman of the Board

Russell Angus has served as our Chairman of the Board since March 2014. Mr. Russell is a veteran in the global biopharmaceutical industry with over 30 years of experience in commercial execution, operations, and strategic acquisitions. He currently serves on the Board of Directors at InterMune, Inc. and Questcor Pharmaceuticals, Inc. and from 1999 to April, 2013, Mr. Russell served as a Director at Shire Plc. During his tenure at Shire Plc, Mr. Russell served as CEO from 2008 to 2013 and CFO from 1999 to 2008. While CEO at Shire, Mr. Russell was also the Chair of Shire's Leadership Team and a lead member of the Shire Management Committee, which designed and implemented Shire's immensely successful long-term business strategy. Prior to joining Shire, Mr. Russell served at ICI, Zeneca, and AstraZeneca, most recently as VP of Corporate Finance at AstraZeneca.

   
Bob Byrnes
Bob Byrnes

Mr. Byrnes has spent over thirty years in the medical device and biotech industry. Most recently from November 2002 to January 2005, he served as the President and Chief Executive Officer of Thermage, Inc. (“Thermage”), a medical device company focused on the non-invasive treatment of wrinkles. From October 1997 until October 2002 and from January 2005 to the present, Mr. Byrnes has served as the President and Chief Executive Officer of Roan, an advisory service for healthcare organizations. Mr. Byrnes has also served as Chairman and Chief Executive Officer of Tokos Medical, President of Caremark and Vice President of Marketing and Business Development for Genentech.

 
Ron Eastman
Ron Eastman
Essex Woodlands Health Ventures

Mr. Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, he has helped build three private healthcare companies -- Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer in 2006.

     
Phyllis Gardner M.D.
Phyllis Gardner M.D.
Essex Woodlands Health Ventures

Dr. Gardner has spent over 25 years in academia, medicine and industry. She began her academic medical career at Stanford University, where she has held several positions including Senior Associate Dean for Education and Student Affairs and remains today as Professor of Medicine. She took a leave of absence to work at ALZA Corporation, a major drug delivery company, as a Principal Scientist, Vice President of Research and as Head of ALZA Technology Institute. She has conducted extensive research in cell biology, including gene therapy, and is widely published in the fields of cell biology and pharmacology. She has received numerous national awards and honors and serves on the Board of Directors of several public and private companies. Dr. Gardner was responsible for Essex Woodlands’ introduction to Rinat Neurosciences, which was acquired by Pfizer, Inc. in April 2006.

   
Julian S. Gangolli
Julian S. Gangolli

Mr. Gangolli is President, North America of GW Pharmaceuticals, spearheading the buildout of the company's U.S. commercial infrastructure in advance of the potential launch of its lead therapeutic candidate, Epidiolex® (cannabidiol or CBD), which is in late-stage development for diverse indications. Prior to joining GW Pharma, Mr. Gangolli served as President of the North American Pharmaceutical division of Allergan Inc. for 11 years, where he was responsible for a 1,400 person integrated commercial operation with sales exceeding $3.8 billion in 2014. Previously, he served as Senior Vice President, U.S. Eye Care at Allergan, during which time this division launched eight new products, helping to propel growth at more than 20% a year over a 5‐year period. Prior to Allergan, Mr. Gangolli served as Vice President, Sales and Marketing at VIVUS, Inc., where he facilitated the successful transition of the company from a research and development start-up into a niche pharmaceutical company. Before VIVUS, Mr. Gangolli served in a number of increasingly senior marketing roles at Syntex Pharmaceuticals, Inc., and Ortho-Cilag Pharmaceuticals Ltd in the UK. Mr. Gangolli received a BSc (Honors) degree in Applied Chemistry and Business Studies from Kingston University in England

     
Philip Vickers
Philip Vickers

Philip J. Vickers, Ph.D. has served as a director since February 2015. Dr. Vickers has spent over 25 years in the pharmaceutical industry. Since 2011, he has been serving as Global Head of Research and Development at Shire where he is responsible for overseeing preclinical research and development, clinical research, regulatory affairs, and medical affairs. Dr. Vickers is also a member of Shire’s Executive and Pipeline Committees. Prior to Shire, he was Chief Scientific Officer and President at Resolvyx Pharmaceuticals, a biopharmaceutical company, from 2009 to 2011, where he was a member of the board of directors. Prior to Resolvyx, he served in various capacities with international biopharmaceutical companies including Boehringer-Ingelheim Pharmaceuticals Inc., Pfizer and Merck Frosst Centre. Dr. Vickers was a Visiting Fellow at the National Cancer Institute in Bethesda, Maryland and holds a Ph.D. in Biochemistry from the University of Toronto, and a B.S. in Applied Biochemistry from the University of Salford, Manchester.

     
= Chair of the Board = Chair = Member
Shareholder Tools